Showing 271-280 of 8349 results for "".
Patient Surveys: When and Why
https://practicaldermatology.com/topics/practice-management/patient-surveys-when-and-why/19112/Todd E. Schlesinger, MD, discusses the benefits of patient surveys and offers tips to get the most out of surveys. Sometimes negative survey responses offer value to the practice--if you use the feedback to improve. Coverage from Vegas Cosmetic Surgery 2014.Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dAK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and ADermWire TV: Factors Affecting Long-term Antibiotic Prescriptions for Acne; Biologics Firm Focusing on Plaque Psoriasis Makes an Important Acquisition; Practical Dermatology Launches Two New Video Series
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-factors-affecting-long-term-antibiotic-prescriptions-acne-biologics-firm-focusing-plaque-psoriasis-makes-important-acquisition-practical-dermatology-launches-two-new-video-series/24319/In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a major acquisition; and Practical Dermatology® launches two new video series focusing on advancing treatment and improving uJournal Club: How Physicians Can Use the New AD Guidelines in Practice
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/how-physicians-can-use-the-new-ad-guidelines-in-practice/24094/In this second part of the inaugural edition of Practical Dermatology's® Atopic Dermatitis (AD) Journal Club, Derek Chu, MD, a key architect of new guidelines for AD management and care, talks with Peter Lio, MD, about his vision for how to make these guidelines easy-to-use and practical for dermatoDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sImproving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with mo